Bempedoic Acid is Used for lowering LDL-C in patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. It was first introduced by Esperion Therapeutics Inc in its drug Nexletol on Feb 21, 2020.

Bempedoic Acid Patents

Given below is the list of patents protecting Bempedoic Acid, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Nexletol	US10118881	Hydroxyl compounds and compositions for cholesterol management and related uses	Dec 23, 2023 (Expired)	Esperion Theraps Inc
Nexletol	US10941095	Hydroxyl compounds and compositions for cholesterol management and related uses	Dec 23, 2023 (Expired)	Esperion Theraps Inc
Nexletol	US11613511	Methods of making bempedoic acid and compositions of the same	Jun 19, 2040	Esperion Theraps Inc
Nexletol	US11744816	Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease	Mar 14, 2036	Esperion Theraps Inc
Nexletol	US11760714	Methods of making bempedoic acid and compositions of the same	Jun 19, 2040	Esperion Theraps Inc
Nexletol	US11926584	Methods of making bempedoic acid and compositions of the same	Jun 19, 2040	Esperion Theraps Inc
Nexletol	US7335799	Hydroxyl compounds and compositions for cholesterol management and related uses	Dec 03, 2030	Esperion Theraps Inc
Nexletol	US8497301	Hydroxyl compounds and compositions for cholesterol management and related uses	Dec 23, 2023 (Expired)	Esperion Theraps Inc
Nexletol	US9000041	Hydroxyl compounds and compositions for cholesterol management and related uses	Dec 23, 2023 (Expired)	Esperion Theraps Inc
Nexletol	US9624152	Hydroxyl compounds and compositions for cholesterol management and related uses	Dec 23, 2023 (Expired)	Esperion Theraps Inc

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳